Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Interview with PMDA Chief Executive Tatsuya Kondo (1)
Aiming to Build a World-class Foundation for Regulatory Science Tatsuya Kondo, MD, PhD, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), discussed his determination to build a world-class pharmaceutical regulatory agency in Japan in an interview with Jiho,…
To read the full story
Related Article
- PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
REGULATORY
- Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
- LDP Launches Alzheimer’s League, Experts Call for Earlier Intervention
July 7, 2026
- LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…